2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) is an analog of the quinoxalinedione antagonists to the non-N-methyl-D-aspartate (non-NMDA) glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine sites. NBQX protects against global ischemia, even when administered 2 hours after an ischemic challenge.
Sheardown
M J
MJ
A/S Ferrosan, CNS Division, Soeborg, Denmark.
Nielsen
E O
EO
Hansen
A J
AJ
Jacobsen
P
P
Honoré
T
T
D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D002545:Brain Ischemia / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D007051:Ibotenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D066298:In Vitro Techniques; D007608:Kainic Acid / Q000494:pharmacology; D016202:N-Methylaspartate; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010069:Oxadiazoles / Q000494:pharmacology; D011712:Pyramidal Tracts / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D011810:Quinoxalines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D016318:Quisqualic Acid; D051381:Rats; D017470:Receptors, Glutamate; D018092:Kainic Acid Receptors; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000378:metabolism; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
D001224:Aspartic Acid; D007051:Ibotenic Acid; D007608:Kainic Acid; D016202:N-Methylaspartate; D010069:Oxadiazoles; D011810:Quinoxalines; D016318:Quisqualic Acid; D017470:Receptors, Glutamate; D018092:Kainic Acid Receptors; D017981:Receptors, Neurotransmitter; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline